Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
5
pubmed:dateCreated
1992-12-22
pubmed:abstractText
Chronic administration of alpha 1-receptor antagonists is associated with loss of clinical efficacy, especially in congestive heart failure, although the mechanism is uncertain. To evaluate changes in venous alpha 1-adrenoceptor responsiveness during chronic alpha 1-adrenoceptor blockade, dose-response curves to phenylephrine and angiotensin II were constructed in 10 healthy subjects before, during, and after administration of terazosin 1 mg orally for 28 d. Terazosin initially shifted the dose-response curve of phenylephrine to the right, with a significant increase in ED50 for phenylephrine from a control value of 102 to 759 ng/min on day 1 of terazosin (P < 0.001). However, by day 28, the dose-response curve had shifted back towards baseline with an ED50 of 112 ng/min. After discontinuing terazosin, the ED50 for phenylephrine remained near the baseline value, indicating no evidence of supersensitivity to phenylephrine. There was no change in responsiveness to angiotensin II during the course of treatment with terazosin. Plasma terazosin concentrations were stable throughout the period of drug administration. The mean Kd of terazosin was estimated as 11 +/- 15 nM in the first few days of treatment. This study demonstrates that pharmacological tolerance to the alpha 1-adrenoceptor blocking action of terazosin occurs in man and may be responsible for loss in efficacy with chronic therapy.
pubmed:grant
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-1671008, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2462300, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2462301, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2462302, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2562959, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2569823, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2572243, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2573445, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2716163, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2848553, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2869077, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2872801, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2872802, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2884849, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2885169, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2894488, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-2899387, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-3018932, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-3025419, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-3029100, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-3524841, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-3548307, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-4042526, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-474434, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-475164, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-495512, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-5063989, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6102572, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6124197, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6166194, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6168865, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6191136, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6254688, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6282526, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6391463, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6520165, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-686171, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-6994759, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7011023, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7014831, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7032827, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7102534, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7213525, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7223592, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7223593, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7223594, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7223616, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7436166, http://linkedlifedata.com/resource/pubmed/commentcorrection/1358918-7460477
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0021-9738
pubmed:author
pubmed:issnType
Print
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1763-8
pubmed:dateRevised
2010-9-7
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Pharmacological tolerance to alpha 1-adrenergic receptor antagonism mediated by terazosin in humans.
pubmed:affiliation
Stanford University, California 94305.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't